Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy

Abstract

AbstractBackgroundLimited real‐world evidence exists on the long‐term clinical outcomes of patients with localized prostate cancer (LPC) who received external beam radiation therapy (EBRT) as the initial treatment. This study evaluated clinical outcomes of US patients with high‐risk LPC (HR‐LPC) and low/intermediate‐risk LPC (LIR‐LPC) who received EBRT.MethodsThis retrospective study using Surveillance, Epidemiology, and End Results‐Medicare linked data from 2012 to 2019 included patients ≥ 65 years old who received EBRT as initial therapy. Baseline patient characteristics were summarized, metastasis‐free survival (MFS), overall survival, and time to initiation of advanced prostate cancer treatment were compared using Kaplan−Meier (KM) and adjusted Cox proportional hazard (PH) models. 5‐year survival probabilities stratified by race/ethnicity (non‐Hispanic [NH] White, NH Black, NH Asian, and Hispanic) were assessed.ResultsOf 11,313 eligible patients, 41% (n = 4600) had HR‐LPC and 59% (n = 6713) had LIR‐LPC. Patient characteristics for both groups were comparable, with mean age at EBRT initiation > 70 years, 86% white, and mean follow‐up time >40 months. More patients in the HR‐LPC than LIR‐LPC groups (78% vs 34%) had concurrent androgen deprivation therapy use and for a longer duration (median 10.4 months vs. 7.4 months). A higher proportion of HR‐LPC patients developed metastasis, died, or received advanced prostate cancer treatment. Adjusted Cox PH survival analyses showed significantly (p < 0.0001) higher risk of mortality (hazard ratios [HR], 1.57 [1.38, 2.34]), metastasis or death (HR, 1.97 [1.78, 2.17]), and advanced prostate cancer therapy use (HR, 2.57 [2.11, 3.14]) for HR‐LPC than LIR‐LPC patients. Within 5 years after the initial EBRT treatment, 18%−26% of patients with HR‐LPC are expected to have died or developed metastasis. The 5‐year MFS rate in the HR‐LPC group was lower than the LIR‐LPC group across all racial/ethnic subgroups. NH Black patients with HR‐LPC had the highest all‐cause mortality rate and lowest rate of receiving advanced prostate cancer treatment, compared to other racial/ethnic subgroups.ConclusionsThis real‐world study of clinical outcomes in patients with LPC treated with EBRT suggests substantial disease burden in patients with HR‐LPC and highlights the need for additional treatment strategies to improve clinical outcomes in patients with HR‐LPC.